NRD
RLAY icon

Nebula Research & Development’s Relay Therapeutics RLAY Stock Holding History

Nebula Research & Development’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-86,641
Closed -$357K – 1119
2024
Q4 		$357K Buy
86,641
+47,057
+119% +$256K 0.04% 669
2024
Q3 		$280K Buy
+39,584
New +$296K 0.03% 740
2024
Q1 		– Sell
-14,314
Closed -$158K – 954
2023
Q4 		$158K Buy
+14,314
New +$121K 0.05% 573

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Nebula Research & Development's RLAY Position: Q1 2025 in Review

Nebula Research & Development sold out of Relay Therapeutics (RLAY) in Q1 2025, closing a stake of 86,641 shares — an estimated $357K sold.

Nebula Research & Development first reported a position in RLAY in Q4 2023 and held it in 3 quarters. The position peaked at $357K in Q4 2024. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

  • Nebula Research & Development reported no remaining Relay Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 86,641 Relay Therapeutics shares in Q1 2025, an estimated $357K.
  • Nebula Research & Development first reported a position in Relay Therapeutics in Q4 2023 and held it in 3 quarters.
  • Nebula Research & Development's Relay Therapeutics position peaked at $357K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.